Your browser doesn't support javascript.
loading
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Miyamoto, Sho; Kuroda, Yudai; Kanno, Takayuki; Ueno, Akira; Shiwa-Sudo, Nozomi; Iwata-Yoshikawa, Naoko; Sakai, Yusuke; Nagata, Noriyo; Arashiro, Takeshi; Ainai, Akira; Moriyama, Saya; Kishida, Noriko; Watanabe, Shinji; Nojima, Kiyoko; Seki, Yohei; Mizukami, Takuo; Hasegawa, Hideki; Ebihara, Hideki; Fukushi, Shuetsu; Takahashi, Yoshimasa; Maeda, Ken; Suzuki, Tadaki.
Afiliación
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kuroda Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kanno T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ueno A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Shiwa-Sudo N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Iwata-Yoshikawa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Sakai Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nagata N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Arashiro T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ainai A; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Moriyama S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kishida N; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Watanabe S; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Nojima K; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Seki Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Hasegawa H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Ebihara H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Takahashi Y; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Maeda K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
iScience ; 26(5): 106694, 2023 May 19.
Article en En | MEDLINE | ID: mdl-37124417
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos